High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150787" target="_blank" >RIV/61989592:15110/14:33150787 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1371/journal.pone.0090458" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0090458</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0090458" target="_blank" >10.1371/journal.pone.0090458</a>

Jazyk výsledku

angličtina

Název v původním jazyce

High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma

Popis výsledku v původním jazyce

Drug repurposing or repositioning is an important part of drug discovery that has been growing in the lask few years for the development of therapeutic options in oncology. We applied this paradigm in a screening of a library of about 3,800 compounds (including FDA-.approved drugs and pharmacologically active compounds) employing a model of metastatic pheochromocytoma, the most common tumor of the adrenal medulla in children and adults. The collection of approved drugs was screened in quantitative mode,testing the compounds in compound-titration series (dose-response curves). Analysis of the dose-response screening data facilitated the selection of 50 molecules with potential bioactivity in pheochromocytoma cells. These drugs were classified based onmolecular/cellular targets and signaling pathways affected, and selected drugs were further validated in a proliferation assay and by flow cytometric cell death analysis. Using metaanalysis information from molecular targets of the top dr

Název v anglickém jazyce

High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma

Popis výsledku anglicky

Drug repurposing or repositioning is an important part of drug discovery that has been growing in the lask few years for the development of therapeutic options in oncology. We applied this paradigm in a screening of a library of about 3,800 compounds (including FDA-.approved drugs and pharmacologically active compounds) employing a model of metastatic pheochromocytoma, the most common tumor of the adrenal medulla in children and adults. The collection of approved drugs was screened in quantitative mode,testing the compounds in compound-titration series (dose-response curves). Analysis of the dose-response screening data facilitated the selection of 50 molecules with potential bioactivity in pheochromocytoma cells. These drugs were classified based onmolecular/cellular targets and signaling pathways affected, and selected drugs were further validated in a proliferation assay and by flow cytometric cell death analysis. Using metaanalysis information from molecular targets of the top dr

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS One

ISSN

1932-6203

e-ISSN

—

Svazek periodika

9

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

"e90458-1"-"e90458-11"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—